Theranostics Market Forecast to Skyrocket, Attaining USD 3,096.47 Million by 2032 with an Astounding CAGR of 10.01% | Key Players- Thermo Fisher Scientific Inc, GE Healthcare, Qiagen NV

Theragnostic is an amalgamation of terminologies, therapeutics, and diagnosis. It is utilized to recount the merger of utilizing one radioactive drug to recognize and subsequent radioactive drug to convey remedy to cure the prominent tumor and any metastatic tumor. Tumor cell has an armor known as a membrane; there are specific proteins, such as somatostatin receptor (SSTR2) on the tumor cell membrane that can be provided as an earmark for cancer drugs. Ga-68 DOTATOC is a radioactive diagnostic drug that earmarks SSTR2. Ga-68 DOTATOC is administered into a patient's vein and traverses covering the bloodstream to all body parts and tissues.

𝐊𝐞𝐲 𝐒𝐭𝐚𝐭𝐬

• The global theranostics market was valued at USD 1,212.39 million in 2022
• The industry is expected to grow at a CAGR of 10.01% during the forecast period
• By 2032, the market is expected to reach USD 3,096.47 million

𝐆𝐞𝐭 𝐘𝐨𝐮𝐫 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰:
https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market/request-for-sample

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

The growing prevalence of cancer worldwide is one of the prominent drivers of the market. As cancer cases grow globally, the demand for more customized and productive cures also escalates. The therapy can assist in recognizing particular cancer biomarkers, which can be utilized to customize treatment schemes for distinct patients.
Furthermore, enhancements in imaging technologies, biomarker recognition, and molecular biology have made it feasible to advance more productive theranostics commodities and services. Additionally, governments globally are funding in research and development of theranostics commodities and services driving up the theranostics market demand.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

The market is excessively aggressive, with customary healthcare mammoths communicating in a zestful way to advance consolidated theranostics solutions. Some of the current players in the theranostics market are:
• F Hoffman La Roche
• Thermo Fisher Scientific Inc.
• GE Healthcare
• Qiagen NV
• Agilent Technologies
• Leica Biosystems Nussloch GmBH
• Pfizer Inc.
• Foundation Medicine
• Beckman Coulter Inc.
• Focus Diagnostics
• Illumina Inc.
• Myriad Genetics Inc.
• AmeriPath Inc.
• Abbott Laboratoriesl

𝐍𝐞𝐞𝐝 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧? 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞: https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market/inquire-before-buying

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

• North America held a dominant position in the global market due to the growing demand for tailor-made medicine and the growing existence of detrimental illnesses. The existence of prominent market players and entrenched healthcare frameworks is anticipated to push market growth.
• Asia Pacific is anticipated to develop at the quickest rate in the market over the forecast period due to the growing demand for customized medicines and the growing existence of detrimental illnesses.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

Theranostics Market, Disease Outlook (Revenue - USD Million, 2019 - 2032)
• Neurological Disorders
• Cardiovascular Diseases
• Oncology Disorders
• Immunological Disorders

Theranostics Market, Technology Outlook (Revenue - USD Million, 2019 - 2032)
• Polymerase Chain Reaction (PCR)
• In Situ Hybridization (ISH)
• Immunohistochemistry (IHC)
• Sequencing

Theranostics Market, End-User Outlook (Revenue - USD Million, 2019- 2032)
• Hospitals and Clinics
• Diagnostics Laboratories
• Others

𝐃𝐢𝐯𝐞 𝐈𝐧𝐭𝐨 𝐭𝐡𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market

𝐓𝐡𝐞𝐫𝐚𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• The Oncology Disorders segment accounted for the largest market share in 2022. Overall, the oncology segment of the theranostics market is expected to continue to grow, driven by increasing awareness of personalized medicine and advances in molecular diagnostics and targeted therapies.

• Based on Technology, the Polymerase Chain Reaction (PCR) segment is anticipated to grow quickly over the forecast period. The PCR segment of the theranostics market is expected to continue to grow, driven by the increasing demand for rapid and accurate diagnostic tests and the development of new PCR-based technologies, such as digital PCR and droplet digital PCR.

• The Hospitals and Clinics segment is accounted to witness the fastest growth rate in the forecast period. The segment growth can be attributed to various factors such as rising number of theranostics patients requiring the diagnosis treatment.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐌𝐑'𝐬 𝐄𝐱𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐨𝐧𝐠𝐨𝐢𝐧𝐠 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐃𝐨𝐦𝐚𝐢𝐧:

Gene Therapy Market: https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market

Hearing Aids Market: https://www.polarismarketresearch.com/industry-analysis/global-hearing-aids-market

Medical Tourism Market: https://www.polarismarketresearch.com/industry-analysis/medical-tourism-market

Medical Disposable Market: https://www.polarismarketresearch.com/industry-analysis/medical-disposable-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.